News

Sherry Soeder, CNP, offers practical suggestions for better survivorship care that follow the standards of care from the Comission on Cancer.

Neoadjuvant chemotherapy (NACT) in treating advanced ovarian cancer has brought improvement s to quality of life and morbidity, but there are still issues within its use, such as choosing the best candidates.

Nivolumab (Opdivo) has been granted FDA approval for the treatment of metastatic or squamous cell carcinoma of the head and neck (SCCHN).

For multiple myeloa and immunotherapy, combination treatment may be the best pathway to durable responses.

"Real Housewives of Beverly Hills" star Camille Grammer discusses how she worked to diminish the shame behind gynecologic cancers.

Brachytherapy is one of three treatments considered standard of care for women with advanced cervical cancer, and it significantly increases the chance of survival. However, less than half of patients with this disease receive standard of care.

Recent development of a tool to detect early signs of cachexia, characterized by muscle loss, anorexia and weakness, in patients with cancer may help with early diagnosis, leading to better prognosis and quality of life.

A number of risk factors can play a role in nonadherence, including older age, memory issues, and depression.

With an election and new president on the horizon, nurses and oncology professionals are wondering what will happen to Vice President Joe Biden's Cancer Moonshot.

Dr. Sundar Jagannath discusses the benefits in progression-free survival and quality of life from newly-approved therapies for patients with multiple myeloma.

Oral Care before, during and after cancer treatment.

For women with breast cancer receiving adjuvant endocrine therapy (AET), adherence may depend on socioeconomic status and out-of-pocket costs.

Genetic testing can be used to stratify the risk of a patient experiencing complications during cancer, such as venous thromboembolism (VTE).

Patients with ovarian cancer often experience recurrence which comes with its own challenges and treatments.

The science linking talcum powder and ovarian cancer is still uncertain.

Immunotherapy expert, Dr. Jeffrey Weber, talks about the importance of early intervention for immune-related adverse events.

The National Coalition for Cancer Survivorship recenly celebrated its 30th anniversary.

The SAMfund and Triage Cancer have partnered to offer financial guidance to cancer patients and caregivers.

Survival in patients with lung cancer could be worse when those patients suffer depression symptoms.

Treatment for sexual pain in women who have been affected by cancer is an unmet need in both oncology and gynecology.

In a recent phase III study, the PARP-inhibitor olaparib was shown to improve progression-free survival for patients with BRCA-positive ovarian cancer.

For survivors suffering from chemotherapy-induced cognitive symptoms, known as "chemobrain," new web-based memory and mental exercises could offer relief.

Despite previous thought, working night shifts does not increase the risk of breast cancer.

Stressing self care, a Mei Fu developed an online platform for prevention and treatment of lymphedema.

Dr. Clayton Lau, a prostate cancer expert, discusses the options for patients with early-stage prostate cancer and the importance of staying educated on this disease.

The Society for Gynecologic Oncology (SGO) released a toolkit of case studies and resources on genetic testing for healthcare providers, patients, and their families.

Survivorship expert Jennifer Klemp talks about optimal survivorship care, the contents of a survivorship plan, measurement of progress and the financial considerations.

A recent study found an increased risk of dementia for patients with prostate cancer being treated with ADT, and those patients with the highest risk had been treated with ADT for the longest period of time.

Denosumab is not inferior to zoledronic acid for treatment of skeletal-related events (SREs) for patients with multiple myeloma, according to a phase III study.

Pembrolizumab gains an FDA approval for frontline therapy of non-small cell lung cancer (NSCLC).